沙特阿拉伯王国政府所属的官方政府网站。
沙特官方政府网站的域名以下列后缀结尾 gov.sa
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
政府网站使用以下协议。 HTTPS 用于加密和安全。
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
The Hong Kong Department of Health (HKDH) found Xiaokeshuping Jiangtangning Jiaonang capsules to contain the undeclared pharmaceutical drugs phenformin, rosiglitazone, and glibenclamide, which may be used in diabetes to lower blood sugar. The HKDH conducted the analysis following receipt of a report that one woman in China had been hospitalized due to a serious hypoglycaemic attack (very low blood sugar) after using Xiaokeshuping Jiangtangning Jiaonang.
Phenformin was previously used for the treatment of diabetes, but was removed from the Canadian market in 1977 and banned in several countries, including Hong Kong, Singapore, Germany, France and the U.S.
Rosiglitazone and glibenclamide are used to lower blood glucose in the treatment of diabetes. These prescription drugs should only be used under the supervision of a healthcare professional.
Phenformin, rosiglitazone, and glibenclamide may cause hypoglycemia (low blood sugar), particularly when combined with other blood glucose-lowering substances.
Xiaokeshuping Jiangtangning Jiaonang capsules are red-and-white in colour. The capsules are contained in a foil package within in a white-and-green box bearing Chinese lettering.
Diabetic patients using other oral anti-diabetic medications in addition to Xiaokeshuping Jiangtangning Jiaonang could suffer serious side effects, including serious, life-threatening hypoglycemia.
Symptoms of hypoglycemia may include sweating, nausea, and trembling, which may lead to headaches and blurred vision. In severe cases, hypoglycemia may cause seizures and coma.
Source: Hong Kong Department of Health
Warning date
最后更新日期: 26/02/2024 at 12:48 上午 Saudi Arabia time
此页面尚未收到任何反馈。
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。